Tigecycline, a derivative of minocycline, is the first available member of the glycylcycline antimicrobial class.

Uses: It is indicated for parenteral treatment of  complicated skin and soft tissue infections, complicated intra-abdominal infections  in adults.

Mechanism of action: Tigecycline exhibits Static action by reversibly binding to the 30S ribosomal subunit and inhibiting protein synthesis.

ANTIBACTERIAL SPECTRUM

Tigecycline exhibits broad-spectrum activity that includes: 

methicillin resistant staphylococci (MRSA),  multidrug-resistant  streptococci,  vancomycin-resistant enterococci (VRE),  extended-spectrum β-lactamase (ESBL) –producing gram negative bacteria,  and  many anaerobic organisms.    

  • However, it  is not active against Proteus, or Pseudomonas species

ADVERSE EFFECTS: As tetrayclines and :

  • ♣ Significant severe nausea ,vomiting and diarrhea  although it is  IV drug.
  • ♣ Acute pancreatitis, including fatality, has been reported with therapy.
  • ♣ Elevations in liver enzymes and serum creatinine
  • ♣ Tigecycline may decrease the clearance of warfarin and increase prothrombin time